Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive once-weekly cagrilintide subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Participants will receive once-weekly semaglutide subcutaneously.
Name:
Tirzepatide
Type:
DRUG
Description:
Participants will receive once-weekly tirzepatide subcutaneously.
Primary Outcomes
Measure:
Change in Glycated Haemoglobin (HbA1c)
TimeFrame:
From baseline (week 0) to end of treatment (week 60)
Description:
Measured in percentage points.
Measure:
Relative Change in Body Weight
TimeFrame:
From baseline (week 0) to end of treatment (week 60)
Description:
Measured in percentage (%).
Trial Information
NCT ID
NCT06534411
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025